Advertisement
Screener

AKEBIA THERAPEUTICS, INC. (AKBA) Stock Issued During Period, Value, Employee Stock Purchase Plan

2.8 / 5 stars · 68/120 Roast Me

AKEBIA THERAPEUTICS, INC. Stock Issued During Period, Value, Employee Stock Purchase Plan

New shares the company issued (share-based compensation, option exercises, employee stock purchase plans, new issues, acquisitions), as filed in its 10-Q and 10-K XBRL statement of shareholders' equity. This is the dilution side; Issuer Repurchases is the other side.

  • AKEBIA THERAPEUTICS, INC. stock issued during period, value, employee stock purchase plan for the quarter ending 2026-03-31 was $131.00K, a 67.95% increase year-over-year.
  • AKEBIA THERAPEUTICS, INC. stock issued during period, value, employee stock purchase plan for the quarter ending 2025-09-30 was $151.00K, a 81.93% increase year-over-year.
  • AKEBIA THERAPEUTICS, INC. stock issued during period, value, employee stock purchase plan for the quarter ending 2025-03-31 was $78.00K, a 11.43% increase year-over-year.
  • AKEBIA THERAPEUTICS, INC. stock issued during period, value, employee stock purchase plan for the quarter ending 2024-09-30 was $83.00K, a 66.00% increase year-over-year.
  • AKEBIA THERAPEUTICS, INC. stock issued during period, value, employee stock purchase plan for fiscal 2025 was $230.00K, a 50.33% increase from fiscal 2024.
  • AKEBIA THERAPEUTICS, INC. stock issued during period, value, employee stock purchase plan for fiscal 2024 was $153.00K, a 80.00% increase from fiscal 2023.
  • AKEBIA THERAPEUTICS, INC. stock issued during period, value, employee stock purchase plan for fiscal 2023 was $85.00K, a 79.27% decline from fiscal 2022.
  • AKEBIA THERAPEUTICS, INC. stock issued during period, value, employee stock purchase plan for fiscal 2022 was $410.00K.
Period endStock Issued During Period, Value, Employee Stock Purchase Plan 3 monthStock Issued During Period, Value, Employee Stock Purchase Plan 12 month
2026-03-31$131.00K
10-Q · filed 2026-08-05
2025-12-31$230.00K
10-K · filed 2026-02-26
2025-09-30$151.00K
10-Q · filed 2025-11-10
2025-03-31$78.00K
10-Q · filed 2026-08-05
2024-12-31$153.00K
10-K · filed 2026-02-26
2024-09-30$83.00K
10-Q · filed 2025-11-10
2024-03-31$70.00K
10-Q · filed 2025-11-10
2023-12-31$85.00K
10-K · filed 2026-02-26
2023-09-30$50.00K
10-Q · filed 2024-11-07
2023-03-31$34.00K
10-Q · filed 2024-11-07
2022-12-31$410.00K
10-K · filed 2024-03-14
2018-12-31$482.00K
10-K · filed 2019-03-26
2017-12-31$353.00K
10-K · filed 2019-03-26
2016-12-31$105.00K
10-K · filed 2019-03-26
2015-12-31$220.00K
10-K · filed 2018-03-12

Similar stocks

Stock NameCountryMarket CapPE Ratio
Lyell Immunopharma, Inc. (LYEL)United States$0.248B-1.32
Pyxis Oncology, Inc. (PYXS)United States$0.244B
Greenwich LifeSciences, Inc. (GLSI)United States$0.267B-15.02
Entrada Therapeutics, Inc. (TRDA)United States$0.243B-1.73
Cue Biopharma, Inc. (CUE)United States$0.243B-1.01
MACROGENICS INC (MGNX)United States$0.242B-20.11
Mereo BioPharma Group plc (MREO)$0.269B-9.41
Camp4 Therapeutics Corp (CAMP)United States$0.240B-2.12
Sionna Therapeutics, Inc. (SION)United States$0.236B-20.37
SIGA TECHNOLOGIES INC (SIGA)United States$0.234B-93.33